Understanding Differential Diagnosis in Acromegaly

Core Clinical Features That Trigger Consideration

Acromegaly arises from chronic excess growth hormone (GH) leading to elevated insulin-like growth factor 1 (IGF‑1). The syndrome progresses slowly, often over years, producing soft-tissue and skeletal changes. Features that commonly prompt evaluation include:

• Enlarging hands and feet with increased shoe or ring size.
• Coarsening facial features such as frontal bossing, enlarged nose, thickened lips, and mandibular prognathism.
• Soft-tissue overgrowth evidenced by widened interdental spacing, macroglossia, and skin thickening.
• Musculoskeletal complaints including joint pain, limited range of motion, and carpal tunnel–type symptoms.
• Metabolic and systemic associations such as hyperhidrosis, headaches, sleep-disordered breathing, hypertension, glucose intolerance, and cardiomyopathy.

Because many of these features overlap with other conditions, distinguishing acromegaly from mimics relies on careful pattern recognition, appropriate laboratory testing, and context from medical history.

Laboratory Foundations in the Differential

Two laboratory concepts anchor the evaluation:

• IGF‑1 concentration: Elevated age- and sex-adjusted IGF‑1 supports GH excess. IGF‑1 integrates GH secretion over time, making it less variable than single GH measurements.
• GH suppression after oral glucose: In acromegaly, GH typically fails to suppress below a defined assay-specific threshold during an oral glucose tolerance test (OGTT).

Interpretation requires awareness of confounders:

• Lower IGF‑1 levels may appear with malnutrition, hypothyroidism, liver disease, poorly controlled diabetes, and chronic kidney disease, potentially masking active disease.
• Physiologic states such as pregnancy and puberty elevate IGF‑1.
• Oral estrogen therapy can lower IGF‑1 and raise GH, altering test performance.
• Assay variability and reference ranges differ by laboratory.

Physiologic and Developmental States That Mimic Acromegaly

Certain normal life stages can produce features reminiscent of GH excess:

• Pregnancy: Fluid retention, soft-tissue changes, skin hyperpigmentation, and nasal congestion may create a fuller facial appearance. Placental GH variants also affect IGF‑1 dynamics. Unlike acromegaly, changes typically resolve postpartum and acral enlargement is limited.
• Puberty: Rapid growth and acne can resemble early features; however, facial coarsening and acral enlargement characteristic of acromegaly are not progressive beyond expected developmental patterns.

Endocrine and Metabolic Conditions With Overlapping Phenotypes

• Severe primary hypothyroidism: Puffy facial features, macroglossia, and coarse skin texture can simulate acromegaly. Bradycardia, weight gain, constipation, dry skin, and markedly elevated TSH favor hypothyroidism. GH-IGF‑1 axis is often suppressed rather than elevated, and features improve with thyroid hormone replacement.
• Insulin-mediated pseudoacromegaly (acromegaloidism): Marked insulin resistance can produce soft-tissue overgrowth, skin tags, acanthosis nigricans, and acral changes with normal GH and IGF‑1. It may occur in severe obesity, lipodystrophy, or genetic insulin signaling defects.
• Poorly controlled diabetes mellitus: Volume shifts and soft-tissue thickening can exaggerate acral appearance, but IGF‑1 tends to be normal or low, and GH suppression is not characteristic.

Skeletal and Dermatologic Disorders That Resemble Acral Overgrowth

• Pachydermoperiostosis (primary hypertrophic osteoarthropathy): Characterized by digital clubbing, periostosis, and thickened, furrowed skin (pachydermia). Onset often in adolescence, with male predominance. Radiographs show periosteal new bone formation. GH and IGF‑1 are typically normal; joint and skin changes can be prominent, resembling acromegaly without classic facial bone overgrowth.
• Paget disease of bone: Presents with skull enlargement, bony deformity, and pain. Alkaline phosphatase is elevated, and radionuclide bone scans reveal focal polyostotic involvement. Facial soft-tissue coarsening is not typical.
• Acromegaloid facial appearance syndromes: Rare genetic conditions can produce coarse facial features with normal GH-IGF‑1 axis. Progression is often limited compared to true acromegaly.

Renal and Hepatic Considerations

• Chronic kidney disease (CKD): Edema, altered skin texture, and metabolic bone disease can mimic aspects of acromegaly. CKD also affects GH clearance and IGF‑1 binding proteins, potentially complicating interpretation of assays. Clinical progression of acral enlargement and classic craniofacial changes is usually absent.
• Chronic liver disease: Changes in IGF‑1 production and sex hormone metabolism may obscure laboratory interpretation. Stigmata of chronic liver disease and imaging findings guide differentiation.

Medications and Exogenous Substances

• Anabolic-androgenic steroids: Can cause seborrhea, acne, fluid retention, and muscle hypertrophy, contributing to a coarser appearance. Absence of progressive acral enlargement and normal IGF‑1 help distinguish.
• Minoxidil and other vasodilators: May cause edema and facial puffiness without true tissue overgrowth.
• Long-term anticonvulsant therapy and retinoids: Occasionally alter soft tissue and bone metabolism but typically lack the full acromegalic pattern.

Distinguishing True Pituitary Acromegaly From Related Entities

• Pituitary adenoma–related acromegaly: Most adult cases stem from a GH-secreting pituitary adenoma. MRI commonly reveals a macroadenoma or microadenoma. Elevated IGF‑1 and absent GH suppression on OGTT support the diagnosis.
• Ectopic growth hormone–releasing hormone (GHRH) secretion: Rare neuroendocrine tumors can secrete GHRH, causing pituitary hyperplasia with biochemical acromegaly. Pituitary imaging may show diffuse enlargement rather than a focal adenoma. Measuring GHRH can clarify this scenario when imaging and clinical context raise suspicion.
• Incidental pituitary lesions: Nonfunctioning pituitary incidentalomas are common and can coexist with acromegaly-like features from other causes. Normal IGF‑1 and appropriate GH suppression suggest the incidentaloma is unrelated.

Musculoskeletal and Neurologic Overlaps

• Osteoarthritis and degenerative joint disease: Hand enlargement from osteophytes and soft-tissue swelling can be mistaken for acromegaly; however, facial changes and metabolic features are absent.
• Carpal tunnel syndrome: Common in acromegaly due to soft-tissue overgrowth, but also prevalent in hypothyroidism, diabetes, pregnancy, and repetitive strain. Diagnosis relies on nerve conduction studies and the broader clinical picture.
• Sleep-disordered breathing: Frequent in acromegaly, but also occurs in obesity and craniofacial anatomic variations. Presence alone is not discriminatory.

Pediatric Considerations: Gigantism vs Other Tall Stature Syndromes

When GH excess occurs before epiphyseal closure, linear overgrowth (gigantism) predominates. Differential diagnosis includes:

• Familial tall stature and constitutional advancement of growth: Normal proportions and growth velocity within familial expectations.
• Marfan syndrome: Tall stature with arachnodactyly, lens dislocation, and aortic root dilation; facial coarsening and soft-tissue thickening are not typical.
• Sotos and Weaver syndromes: Overgrowth with developmental features; GH-IGF‑1 axis may be normal.
• Hyperthyroidism and precocious puberty: Accelerated growth velocity without acral and soft-tissue changes characteristic of GH excess.

In suspected gigantism, elevated IGF‑1 relative to age and incomplete GH suppression on OGTT support GH excess, while pituitary imaging aids localization.

Imaging Pearls and Pitfalls

• MRI of the sellar region is the imaging study of choice for pituitary evaluation. Microadenomas may be subtle; dynamic contrast sequences improve detection.
• Diffuse pituitary enlargement without a discrete mass suggests hyperplasia, potentially from ectopic GHRH or physiologic states.
• Skull and hand radiographs can show cortical thickening, enlarged frontal sinuses, and tufting of distal phalanges in acromegaly; however, similar changes may appear in pachydermoperiostosis and other conditions.

An Approach to the Differential Diagnosis

A structured approach can reduce misclassification:

1. Document the tempo and pattern of changes: Progressive acral enlargement and facial coarsening favor acromegaly; abrupt edema suggests alternative causes.
2. Review systemic context: Pregnancy, thyroid status, renal and hepatic function, medication history, and features of insulin resistance inform pretest probability.
3. Measure age-adjusted IGF‑1: Elevated values prompt confirmatory testing; normal results with strong clinical suspicion may warrant repeat testing or evaluation for confounders.
4. Perform GH suppression testing when indicated: Lack of suppression supports active acromegaly; borderline or discordant results call for review of confounders and assay specifics.
5. Image the pituitary: Identify adenoma, hyperplasia, or incidental findings; consider ectopic sources if pituitary findings are nonfocal with biochemical confirmation of GH excess.
6. Reassess alternative diagnoses when labs are inconsistent: Hypothyroidism, CKD, severe insulin resistance, and genetic acromegaloid syndromes often demonstrate normal or suppressed GH-IGF‑1 axes.

Recognizing Confounders and Discordant Results

Discordance between clinical appearance, IGF‑1, and GH suppression can occur. Common scenarios include:

• Low IGF‑1 in active disease due to malnutrition, liver disease, or assay issues.
• Elevated GH with normal IGF‑1 from assay variability, oral estrogen use, or acute illness.
• Pseudoelevation of IGF‑1 in pregnancy and puberty.

Repetition of testing after addressing reversible factors and using consistent laboratories helps clarify uncertain cases.

Key Takeaways

• Acromegaly is a clinical-biochemical diagnosis supported by elevated age-adjusted IGF‑1 and failure of GH suppression on OGTT, typically with a pituitary adenoma on imaging.
• Multiple conditions mimic aspects of acromegaly, including hypothyroidism, insulin-mediated pseudoacromegaly, pachydermoperiostosis, Paget disease, CKD, pregnancy, and medication effects.
• Careful attention to onset, progression, systemic context, and targeted testing helps distinguish true GH excess from look-alike states and avoids misinterpretation of incidental imaging findings.